A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers

Trial Profile

A Phase 1 Study of MM-121 in Combination With Cetuximab and Irinotecan in Patients With Advanced Cancers

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Seribantumab (Primary) ; Cetuximab; Irinotecan
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Merrimack Pharmaceuticals
  • Most Recent Events

    • 16 Nov 2016 Results analysing safety, pharmacokinetics and efficacy published in the Investigational New Drugs.
    • 28 Apr 2016 No of arms changed from 1 to 2 in which treatment is divided into two parts as per ClinicalTrials.gov record.
    • 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top